Progetto vincitore della Borsa di Studio SISA 2017 - Palma

 

 

 

Galectin-3 and Lp(a) levels in serum and atherosclerotic plaques of patients undergoing carotid endarterectomy

Daniela Palma

 


Abstract:


Background/rationale. Atherosclerosis consists in the development of plaque in the intima-.media layers of big arteries due to lipid accumulation and oxidation together with a massive inflammation. Plaque instability is the most relevant risk factor for acute events. Galectin-3 (Gal-3) is a pleiotropic protein involved in macrophage chemotaxis, phagocytosis, oxidative stress, cell proliferation, extracellular matrix remodeling. Lipoprotein(a) - Lp(a) is a modified LDL particle which increased levels are considered a cardiovascular risk factor since it is able to amplify inflammatory and proliferative responses and trigger atherogenic and prothrombotic mechanisms in the arteries. Poor data are currently available about the evaluation of these molecules in human atherosclerotic plaques.

 

Objectives. We aim to better understand the role of Gal-3 and Lp(a) in atherosclerotic process (aim 1) and to define their potential role as markers of plaque instability (aim 2) through an integrated study of serum levels, plaque levels, plaque characteristics at histological analysis and clinical data of patients undergoing carotid endarterectomy.

 

Methods and research strategy. We will measure Gal-3 and Lp(a) in the serum of at least 100 patients undergoing carotid endarterectomy. Plaques will be characterized histologically to perform the classification, the identification of instability features. In a subset of 20 patients the quantification of Gal-3 and Lp(a) in plaque and in their adjacent regions will be performed by immunohistochemistry and Gal-3 mRNA levels will be evaluated in plaques and in peripheral leukocytes. Data about Gal-3 and Lp(a) levels in serum and plaques will be correlated with plaque characteristics in order to evaluate if they have a prominent role in plaque instability.

 

Expected results. The overall results will clarify if Gal-3 and Lp(a) levels in serum and plaques are related to plaque development and to plaque instability.


 

 

 

Area Soci

Eventi

38° Congresso Nazionale


38° Congresso Nazionale

Bologna, 1-3 dicembre 2024
Abstract deadline
7 ottobre 2024

[continua a leggere]

Congresso Regionale SISA Sezione Lombardia

Milano, 10-12 Ottobre 2024

[continua a leggere]

Congresso Multiregionale SISA Adriatica e SIIA Umbro-Marchigiana

Ancona, 4-5 Ottobre 2024

[continua a leggere]

Congresso Regionale SISA Sezione Sardegna

Cagliari, 4-5 Ottobre 2024

[continua a leggere]

SISA LIPID ACADEMY - Corso avanzato di lipidologia clinica

Modena, 4-5 Luglio 2024

[continua a leggere]

Giornale Italiano Arteriosclerosi

Rivista in lingua italiana
riservata ai Soci SISA
Ultimo numero:
Anno 15 • N.2/2024

[continua a leggere]

HoFH today

Rivista Italiana della
Ipercolesterolemia
Familiare Omozigote
Anno 5 • N.1/2023

[continua a leggere]

Rivista NMCD

Nutrition, Metabolism and Cardiovascular Diseases

Istruzioni per l'accesso online

IF 2018: 3.340


Diateca

EAS Lipid Clinic Webinar - Le linee guida per le dislipidemie: presente e futuro
[continua a leggere]
EAS Advanced Course in Rare Lipid Disease
[continua a leggere]

Newsletter

Per essere informati sulle novità di S.I.S.A. iscrivetevi alla nostra newsletter inserendo
il vostro indirizzo di posta elettronica

Progetto LIPIGEN

LIPIGEN
Nuovo sito dedicato al Progetto LIPIGEN

 

Progetto LIPIGEN - Vecchio portale
E' necessario essere loggati come utente
Lipigen per poter accedere alla pagina

PROject Statin Intolerance SISA

 

PROSISA – PROject Statin Intolerance SISA
E' necessario essere loggati come utente
PROSISA per poter accedere alla pagina

GILA - Lipoprotein Aferesi

 

Gruppo Interdisciplinare Lipoprotein Aferesi
(Accesso Gruppo GILA-Lipoprotein Aferesi)

E' necessario essere loggati come utente del Gruppo GILA per poter accedere

 

Gruppo Interdisciplinare Lipoprotein Aferesi
(Documentazione ad accesso libero)

Pagina informativa per medici e pazienti